Semaglutide vs Topiramate for Weight Loss: Which Medication Works Better in 2026?

Jennifer sat in my office last month, frustrated after six weeks on topiramate. Her neurologist had prescribed it off-label for weight loss after years of failed diets. "I've lost maybe eight pounds, but I can't remember words," she told me, tearing up. "Yesterday I couldn't think of the word for 'refrigerator' during a work presentation." This scenario plays out more often than you'd think, as patients discover that topiramate's cognitive side effects—nicknamed "Dopamax" by many who've tried it—can significantly impact quality of life, even when the medication produces modest weight loss.

The comparison between semaglutide and topiramate isn't just academic. It represents two completely different philosophies in weight management medicine. Topiramate is an anticonvulsant that was never designed for weight loss but happens to suppress appetite through mechanisms we don't fully understand. Semaglutide, on the other hand, is a GLP-1 receptor agonist that mimics a natural hormone your body already produces to regulate blood sugar and appetite. One is a repurposed seizure medication with off-label use; the other is an FDA-approved weight management treatment backed by some of the most impressive clinical trial data we've ever seen in obesity medicine.

How These Medications Work Differently in Your Body

Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone your intestines naturally release after eating. This hormone does several things simultaneously: it signals your brain that you're full, slows down how quickly food leaves your stomach, and helps regulate blood sugar levels. When you take semaglutide, you're essentially amplifying a signal your body already understands. The medication binds to GLP-1 receptors throughout your body, particularly in the brain regions that control appetite and food intake.

The beauty of this mechanism is its elegance. You're not fighting your body's natural processes—you're working with them. Patients typically describe feeling satisfied with smaller portions without the uncomfortable "stuffed" feeling. They'll often say things like, "I just forget to think about food" or "I can finally hear my actual hunger signals." In our clinical experience, this translates to sustainable behavior changes that extend beyond just medication use.

Topiramate's mechanism is far murkier. It's primarily an antiepileptic drug that affects multiple neurotransmitter systems, including GABA enhancement and glutamate inhibition. We think it suppresses appetite through effects on the hypothalamus and possibly by making food taste different—many patients report that carbonated beverages taste flat or that they develop taste changes that make eating less appealing. Some researchers believe it may also affect how your body stores fat and processes glucose, but these mechanisms aren't well-defined.

The problem with topiramate's approach is that it's essentially creating side effects that happen to include weight loss. You're not targeting appetite regulation specifically; you're affecting multiple brain systems simultaneously, which explains why cognitive side effects are so common. Patients describe mental fog, difficulty finding words (called anomia), memory problems, and slowed thinking. For some people, these cognitive changes are subtle. For others, like Jennifer, they're career-threatening.

What the Clinical Evidence Actually Shows

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity who received either semaglutide 2.4 mg weekly or placebo, along with lifestyle interventions. After 68 weeks, participants on semaglutide lost an average of 14.9% of their body weight compared to just 2.4% in the placebo group. Even more impressive: nearly 70% of people on semaglutide lost at least 10% of their body weight, and almost one-third lost 20% or more. These numbers represent a fundamental shift in what's possible with medical weight management.

Topiramate's evidence base looks considerably different. Most studies have used it in combination with phentermine (the Qsymia combination), making it difficult to assess topiramate alone. When used as monotherapy for weight loss, studies show an average weight loss of about 6-7% of body weight over 6-12 months—roughly half of what we see with semaglutide. A 2014 Cochrane review analyzing multiple topiramate trials found that at doses of 176-200 mg daily, patients lost an additional 6.5 kg (about 14 pounds) compared to placebo over one year.

But here's what matters just as much as the numbers: completion rates and quality of life. In the STEP 1 trial, about 83% of participants completed the full 68-week study. With topiramate, discontinuation rates in clinical trials range from 30-50%, primarily due to side effects. That's a massive difference. A medication can't help you if you can't tolerate taking it.

We've also got impressive cardiovascular data for semaglutide now. The SELECT trial, published in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in people with obesity and established cardiovascular disease. This was groundbreaking—it showed that semaglutide isn't just a weight loss medication, it's potentially a cardiovascular protective therapy. Topiramate has no comparable cardiovascular outcomes data, and in fact, some studies suggest it may increase heart rate in certain patients.

Side Effect Profiles: What to Actually Expect

When starting semaglutide, the most common side effects are gastrointestinal: nausea, occasional vomiting, diarrhea, and constipation. In our patients, we see nausea in perhaps 40-50% of people when first starting or increasing doses, but it's typically mild to moderate and improves significantly within a few weeks. The key is proper dose escalation—starting low and increasing gradually allows your body to adapt.

Real talk: the nausea is rarely fun, but it's manageable with straightforward strategies. Eating smaller meals, avoiding high-fat foods, staying hydrated, and not lying down immediately after eating all help. Most patients tell us that after the first month or two, GI side effects become minimal or disappear entirely. We don't see the cognitive impairment, personality changes, or neurological symptoms that topiramate commonly causes.

Topiramate's side effect profile is more concerning for many patients. Beyond the cognitive issues I mentioned earlier—word-finding difficulties, memory problems, confusion, slowed thinking—there are other significant risks. Topiramate can cause tingling in the hands and feet (paresthesias), which affects up to 50% of users. It increases the risk of kidney stones. It can cause metabolic acidosis, a dangerous change in your blood chemistry. There's an increased risk of acute angle-closure glaucoma, a sight-threatening emergency that can occur within the first month of treatment.

The medication also carries serious pregnancy warnings. Topiramate is associated with an increased risk of cleft lip and palate in babies exposed during the first trimester, which is why women of childbearing age need reliable contraception while taking it. Semaglutide should also be stopped before planned pregnancy, but we don't have the same level of teratogenic concern documented in human studies.

Perhaps most concerning is what we call the risk-benefit calculation. With semaglutide, you're getting substantial weight loss (average 15% of body weight) with primarily manageable, temporary GI side effects. With topiramate, you're getting modest weight loss (average 6-7% of body weight) while accepting risks to cognitive function, vision, kidney health, and more. For most patients, that math doesn't add up favorably.

Cost, Access, and Practical Considerations

Brand-name Wegovy (semaglutide for weight loss) has a list price around $1,300-$1,500 per month without insurance. That's prohibitively expensive for most people. However, compounded semaglutide—which Ozari Health offers—provides the same active ingredient at a fraction of the cost, often starting at $99/month. This has democratized access considerably over the past couple of years.

Topiramate is available as an inexpensive generic, typically costing $10-30 per month even without insurance. On paper, it looks like the budget-friendly option. But this calculation changes when you factor in the real-world experience. If you can't tolerate the medication and discontinue it within a few months, you haven't saved money—you've wasted time and delayed finding an effective treatment.

There's also the matter of administration. Semaglutide requires a weekly subcutaneous injection using a small insulin-like pen. Most patients find this easier than they expected—the needles are tiny, and once weekly is convenient. Topiramate is a daily pill, which sounds simpler but requires remembering medication every single day and often involves dose adjustments that mean splitting pills or taking multiple tablets.

Insurance coverage varies wildly for both medications. Some insurance plans cover Wegovy for weight loss if you meet specific BMI criteria and have weight-related comorbidities. Others don't cover it at all, considering it a lifestyle medication. Topiramate is usually covered when prescribed for its FDA-approved indications (epilepsy, migraine prevention), but insurance may question off-label use for weight loss.

What Women Should Know

Women need to be particularly cautious with topiramate due to the pregnancy risks I mentioned. If there's any chance of pregnancy, you need highly effective contraception while taking topiramate—and be aware that topiramate can reduce the effectiveness of hormonal birth control pills. You might need to use backup contraception or switch to non-hormonal methods like an IUD.

Women also appear to experience cognitive side effects from topiramate somewhat more frequently than men in some studies, though this isn't definitively established. What we do know is that women often bear the mental load of family management, work responsibilities, and multiple competing demands—cognitive impairment isn't just inconvenient, it can be genuinely disruptive to daily life.

With semaglutide, women should plan to discontinue the medication at least two months before attempting to conceive, as we don't have extensive data on pregnancy outcomes. However, losing significant weight before pregnancy can actually improve fertility and pregnancy outcomes for women with obesity, particularly those with polycystic ovary syndrome (PCOS). We've seen numerous patients who struggled with infertility achieve successful pregnancies after weight loss with semaglutide, followed by an appropriate washout period.

What Men Should Know

Men often tolerate higher doses of topiramate with fewer reported side effects than women, though cognitive issues still occur frequently. The bigger consideration for men is often the carbonation taste change—if you're someone who enjoys beer or soda regularly, be prepared for these to taste completely flat and unappealing on topiramate. Some guys find this helpful for cutting calories; others find it surprisingly bothersome.

With semaglutide, men frequently see impressive results, often losing weight slightly faster than women in the first few months. Part of this is physiological—men typically have more muscle mass and higher baseline metabolic rates. We've noticed that men are sometimes more hesitant about the injection aspect initially, but they adapt quickly and often appreciate the once-weekly convenience compared to daily medications.

For men concerned about cardiovascular health—which becomes increasingly relevant after age 45—the SELECT trial data is particularly relevant. The 20% reduction in major cardiovascular events gives semaglutide a preventive health benefit that topiramate simply doesn't offer. If you're carrying excess weight and have risk factors like high blood pressure or a family history of heart disease, this cardiovascular protection is worth serious consideration.

From the Ozari Care Team

We recommend approaching weight loss medication as a tool that should enhance your quality of life, not diminish it. If a medication is making you feel mentally foggy, unable to do your job effectively, or experiencing side effects that interfere with daily activities, it's not the right choice regardless of what the scale says. In our experience, semaglutide offers the best combination of effectiveness, tolerability, and additional health benefits for the vast majority of patients seeking medical weight management. What we tell our patients is simple: you deserve a treatment that works with your body's natural systems and lets you feel like yourself while losing weight.

Key Takeaways

• Semaglutide produces roughly twice the weight loss of topiramate (average 15% vs. 6-7% of body weight) with better completion rates in clinical trials
• Topiramate's cognitive side effects—including word-finding difficulties, memory problems, and mental fog—affect a substantial percentage of users and can impact work performance and daily life
• Semaglutide offers proven cardiovascular benefits (20% reduction in major cardiac events in the SELECT trial), while topiramate has no comparable cardiovascular outcomes data
• While generic topiramate costs less upfront ($10-30/month), compounded semaglutide at $99/month through providers like Ozari Health offers significantly better results for a modest cost increase
• Women considering topiramate must use reliable contraception due to birth defect risks; semaglutide requires a two-month washout before planned pregnancy but doesn't affect contraceptive effectiveness

Frequently Asked Questions

Can you take semaglutide and topiramate together for weight loss?

While there's no absolute contraindication to using these medications together, it's rarely done in clinical practice and we generally don't recommend it. Combining them doesn't produce additive benefits that justify taking two medications with different side effect profiles. Semaglutide alone typically produces sufficient weight loss that adding topiramate isn't necessary, and layering medications increases the complexity of figuring out which drug is causing which side effects if problems arise. If you're not getting adequate results with semaglutide alone, we'd typically optimize the dose or consider switching to tirzepatide rather than adding topiramate.

How long does it take to see weight loss results with each medication?

With semaglutide, most patients notice reduced appetite within the first week or two, and measurable weight loss typically begins within the first month. The weight loss continues progressively over 60-68 weeks as you reach the full maintenance dose, with the most dramatic changes usually happening in months 2-6. Topiramate works somewhat faster initially—some patients see results within 2-3 weeks—but the total amount of weight loss plateaus earlier, usually by 6-9 months. That said, topiramate's faster onset doesn't matter much if you can't tolerate the medication long enough to see sustained results.

Will insurance cover semaglutide or topiramate for weight loss?

Insurance coverage is complicated for both medications. Topiramate is usually covered for its FDA-approved uses (epilepsy and migraine prevention), but insurers may deny coverage for off-label weight loss prescribing. Wegovy, the brand-name semaglutide for weight loss, is covered by some commercial insurance plans if you meet specific criteria—usually a BMI over 30 or BMI over 27 with weight-related health conditions—but many plans still exclude weight loss medications entirely. This is precisely why compounded semaglutide has become such an important option, providing access at $99-$299/month regardless of insurance coverage, making it affordable for people who would otherwise pay $1,500/month or go without treatment.

What happens when you stop taking these medications?

This is a critical question that doesn't get discussed enough. With both medications, some weight regain is common after discontinuation, though the amount varies considerably between individuals. In the STEP 1 trial extension, participants who stopped semaglutide regained about two-thirds of their lost weight over the following year, though they still maintained some benefit compared to baseline. With topiramate, weight regain after stopping is often rapid and complete within months. The key insight here is that obesity is a chronic condition, and these medications work while you're taking them—they're not a temporary fix that permanently resets your metabolism. Many patients choose to continue semaglutide long-term at a maintenance dose because the benefits extend beyond just weight (cardiovascular protection, improved metabolic health), while topiramate's side effect profile makes long-term use less appealing for most people.

Which medication is safer for long-term use?

Based on current evidence, semaglutide has a more favorable safety profile for long-term use. GLP-1 medications have been used for diabetes management since 2005, giving us nearly two decades of safety data, and the side effects are primarily temporary GI symptoms that improve with time. Topiramate's cognitive effects, kidney stone risk, and potential for vision problems make long-term use concerning for many clinicians, especially when prescribing it off-label for weight loss rather than for its approved indications. The SELECT trial followed patients on semaglutide for over three years and demonstrated not just safety but actual cardiovascular benefit, which is remarkable. We're comfortable recommending semaglutide for extended use in appropriate patients, whereas with topiramate, we're constantly weighing whether the modest weight loss benefit justifies continued exposure to neurological and metabolic risks.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, shipped to your door. Learn more at ozarihealth.com.